Modality
Bispecific Ab
MOA
PD-L1i
Target
PRMT5
Pathway
STING
Gastric CaUrothelial Ca
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Sep 2028
Phase 1Current
NCT07518880
1,949 pts·Gastric Ca
2020-10→2028-09·Active
1,949 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-257mo agoConference· Urothelial Ca
2028-09-282.5y awayInterim· Gastric Ca
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Active
Catalysts
Conference
2025-08-25 · 7mo ago
Urothelial Ca
Interim
2028-09-28 · 2.5y away
Gastric Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07518880 | Phase 1 | Gastric Ca | Active | 1949 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |